Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
<p>BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, today announced that it has received a deficiency letter (“Letter”) from NYSE American LLC (“NYSE American” or the “Exchange”) […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/matinas-biopharma-announces-notification-of-nyse-american-continued-listing-deficiency/">Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>
Leave a Comment